Failure of ibogaine to produce phencyclidine-like discriminative stimulus effects in rats and monkeys

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 2, 1998, Pages 413-418

  Jones, Hendrée E ^a   Li, Hua ^a   Balster, Robert L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug discrimination; Ibogaine; LSD; Lysergic acid diethylamide; N methyl D aspartate; NMDA; PCP; Phencyclidine

Indexed keywords

IBOGAINE; LYSERGIDE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG ABUSE; DRUG DEPENDENCE; DRUG DISCRIMINATION; HYPOTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; RHESUS MONKEY;

EID: 0032005724     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00452-8     Document Type: Article

References (35)

1. Balster R. L. Discriminative stimulus properties of phencyclidine and other NMDA antagonists. Glennon R. A., Järbe T. U. C., Franknheim J. Drug discrimination. Applications to drug abuse research:1991;163-180 DHHS, National Institute on Drug Abuse Research Monograph, 116. Rockville, MD.
2. Balster R. L., Mansbach R. S., Shelton K. L., Nicholson K. L., Grech D. M., Wiley J. L., Li H., Weber E. Behavioral pharmacology of two novel substituted quinoxalinedione glutamate antagonists. Behav. Pharmacol. 6:1995;577-589.
3. Browne R. G., Welch W. M., Kozlowski M. R., Duthu G. Antagonism of PCP discrimination by adenosine analogs. Kamenka J. M., Domino E. F., Geneste P. Phencyclidine and related arylcyclohexylamines. Present and future applications:1983;639-649 NPP Books, Ann Arbor.
4. Cappendijk S. L. T., Dzoljic M. R. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur. J. Pharmacol. 241:1993;261-265.
5. Cohen B. D., Rosenbaum G., Luby E. D., Gottlieb J. S. Comparison of phencyclidine hydrochloride (serynl) with other drugs. Arch. Gen. Psychol. 6:1962;395-401.
6. Deecher D. C., Teitler M., Soderlund D. M., Bornmann W. G., Kuehne M. E., Glick S. D. Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 571:1992;242-247.
7. Dworkin S. I., Gleeson S., Meloni D., Koves T. R., Martin T. J. Effects of ibogaine on responding maintained by food, cocaine and heroin reinforcement in rats. Psychopharmacology (Berlin). 117:1995;257-261.
8. Glick S. D., Rossman K., Steindorf S., Maisonneuve I. M., Carlson J. N. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:1991;341-345.
9. Glick S. D., Rossman K., Wang S., Don N., Keller R. W. Jr. Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum. Interactions with d-amphetamine Brain Res. 628:1993;201-208.
10. Gorelick D. A., Balster R. L. Phencyclidine (PCP). Bloom F. E., Kupfer D. J. Psychopharmacology. The fourth generation of progress:1995;1767-1776 Raven Press, New York.
11. Herman B. H., Vocci F., Bridge P. The effects of NMDA receptor antagonists and nitric oxide synthase inhibitors on opioid tolerance and withdrawal. Neuropsychopharmacology. 13:1995;269-293.
12. Lotsof, H.: Rapid method for interrupting the narcotic addiction syndrome. U.S. Patent No. 4,499,096; 1985.
13. Lotsof, H.: Rapid method for interrupting the cocaine and amphetamine abuse syndrome. U.S. Patent No. 4,587,243; 1986.
14. Maisonneuve I. M., Keller R. W., Glick S. D. Interactions between ibogaine, a potential anti-addictive agent, and morphine. An in vivo microdialysis study Eur. J. Pharmacol. 199:1991;35-42.
15. Maisonneuve I. M., Keller R. W., Glick S. D. Interactions of ibogaine and D-amphetamine. In vivo microdialysis and motor behavior in rats Brain Res. 579:1992;87-92.
16. Maisonneuve I. M., Rossman K. L., Keller R. W. Jr., Glick S. D. Acute and prolonged effects of ibogaine on brain dopamine metabolism and morphine-induced locomotor activity in rats. Brain Res. 575:1992;69-73.
17. Mash D. C., Staley J. K., Pablo J. P., Holohean A. M., Hackman J. C., Davidoff J. C. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 192:1995;53-56.
18. Nielsen E. B. Discriminative stimulus properties of lysergic acid diethylamide in the monkey. J. Pharmacol. Exp. Ther. 234:1985;244-249.
19. Palumbo P. A., Winter J. C. Stimulus effects of ibogaine in rats trained with yohimbine, DOM, or LSD. Pharmacol. Biochem. Behav. 43:1992;1221-1226.
20. Pollard J. C., Uhr L., Stern E. Drugs and phantasy. The effects of LSD, psilocybin and sernyl on college students:1965;Little, Brown and Co, Boston.
21. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology (Berlin). 114:1994;672-674.
22. Rosenbaum G., Cohen B. D., Luby E. D., Gottlieb J. S., Yelen D. Comparison of sernyl with other drugs. Arch. Gen. Psychol. 1:1959;651-656.
23. Schechter M. D., Gordon T. L. Comparison of the behavioral effects of ibogaine from three sources. Mediation of discriminative activity Eur. J. Pharmacol. 249:1993;79-84.
24. Sershen H., Harsing L. G., Hashim A., Lajtha A. Ibogaine reduces amphetamine-induced locomotor stimulation in C57BL/6By mice, but stimulates locomotor activity in rats. Life Sci. 51:1992;1003-1011.
25. Sershen H., Hashim A., Harsing L., Lajtha A. Ibogaine antagonizes cocaine-induced locomotor stimulation in mice. Life Sci. 50:1992;1079-1086.
26. Sershen H., Hashim A., Lajtha A. Ibogaine reduces preference for cocaine consumption in C57BL/6By mice. Pharmacol. Biochem. Behav. 47:1994;13-19.
27. Sershen H., Hashim A., Lajtha A. Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats. Neurochem. Res. 19:1994;1463-1466.
28. Shannon H. E. Evaluation of phencyclidine analogs on the basis of their discriminative stimulus properties in the rat. J. Pharmacol. Exp. Ther. 216:1981;543-551.
29. Sheppard S. G. A preliminary investigation of ibogaine. Case reports and recommendations for further study J. Subst. Abuse Treat. 11:1994;379-385.
30. Sloviter R. S., Drust E. G., Damiano B. P., Connor J. D. A common mechanism for lysergic acid, indole alkylamine, and phenethylamine hallucinogens. Serotonergic mediation of behavioral effects in rats J. Pharmacol. Exp. Ther. 214:1980;231-238.
31. Sweetnam P. M., Lancaster J., Snowman A., Collins J. L., Perschke S., Bauer C., Ferkany J. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology (Berlin). 118:1995;369-376.
32. Trujillo K. A., Akil H. Excitatory amino acids and drugs of abuse. A role for N-methyl-D-aspartate receptors in drug tolerance, sensitization and physical dependence Drug Alcohol Depend. 38:1995;139-154.
33. Willetts J., Balster R. L. Phencyclidine-like discriminative stimulus properties of MK-801 in rats. Eur. J. Pharmacol. 146:1988;167-169.
34. Willetts J., Balster R. L., Leander J. D. The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol. Sci. 11:1990;423-428.
35. Woods J. H., Koek W., France C. P., Moerschbaecher J. M. Behavioral effects of NMDA antagonists. Meldrum B. S. Excitatory amino acid antagonists. 1991;237-264 Blackwell Scientific Publications, Oxford.